No Result
View All Result
No Result
View All Result
No Result
View All Result

GHK-Cu (Copper Tripeptide-1) | Ingredient Overview: Pharmacokinetics, Formulations, Human Research Evidence, Safety, and Combinations

by SHIZAM Editorial Team
June 12, 2026

GHK-Cu, also called Copper Tripeptide-1, is a copper-binding tripeptide complex of glycyl-L-histidyl-L-lysine that occurs naturally in the human body and has been studied mainly in topical skin, diabetic skin-ulcer, skin-delivery, and tissue-remodeling research (Review).

GHK-Cu is best understood as a topical and mechanistic copper peptide, not as a conventional oral supplement ingredient. Human studies have evaluated GHK-Cu mainly as a topical ingredient for skin appearance, post-procedure skin recovery, and diabetic skin-ulcer healing (Research) (Research). Human evidence outside topical skin and wound contexts remains limited, and many broader claims rely on human-cell, animal, or mechanistic research rather than clinical outcomes in people (Review).

Ingredient Identity

  • Official name(s): GHK-Cu; Copper Tripeptide-1; glycyl-L-histidyl-L-lysine copper complex (PubChem).
  • Synonyms: Copper tripeptide, copper peptide GHK-Cu, prezatide copper, copper complex of Tripeptide-1 (PubChem).
  • Classification: Copper-binding tripeptide / peptide-copper complex (Review).
  • CAS number: PubChem maintains a chemical record for copper tripeptide, while cosmetic ingredient databases may identify Copper Tripeptide-1 by INCI name rather than by a single reader-facing CAS number (PubChem) (EFSA).
  • Endogenous vs exogenous: GHK is described as a naturally occurring human peptide, while topical GHK-Cu products provide external exposure through skin application (Review).

Ingredient Snapshot

  • Classification: GHK-Cu is a copper complex of a short peptide made from glycine, histidine, and lysine (Review).
  • Endogenous vs exogenous status: GHK occurs naturally in human biological fluids, while cosmetic and research products use externally applied Copper Tripeptide-1 or related GHK-Cu forms (Review).
  • Primary human research domains: Human research is concentrated in Beauty and Skin Health, post-procedure skin recovery, diabetic skin-ulcer healing, and human-skin delivery studies (Research) (Research) (Research).
  • Common study formats: The evidence base includes topical clinical studies, ex vivo human-skin penetration studies, human-cell mechanistic studies, and narrative reviews (Research) (Research) (Review).
  • Pharmacokinetic characterization status: Human systemic pharmacokinetic values such as Tmax and half-life are not well characterized for topical GHK-Cu in the available human literature (Research).
  • Regulatory context: In the U.S., cosmetic products and ingredients generally do not need FDA premarket approval except color additives, but companies remain responsible for safety and labeling compliance (FDA). FDA separately identifies injectable-route GHK-Cu in compounding safety-risk materials because of limited human safety data and possible immunogenicity concerns (FDA).
  • Evidence maturity: The overall evidence base is Limited / Emerging because human evidence is small and skin-focused, while many broader claims remain mechanistic or preclinical (Review).

Introduction

GHK-Cu is a copper-binding peptide complex based on the naturally occurring tripeptide GHK. Reviews describe GHK as present in human plasma, saliva, and urine, while GHK-Cu is commonly discussed as a copper-complexed form relevant to skin repair and tissue remodeling research (Review).

People often look up GHK-Cu because it appears in cosmetic peptide products, skin-aging discussions, and wound-healing research. The human evidence is much narrower than many public claims suggest: it mainly covers topical skin studies, diabetic skin-ulcer healing, post-procedure skin recovery, and skin-delivery models (Research) (Research).

This article is informational only, describes GHK-Cu as a biochemical substance studied in human research, and does not provide medical or dosing advice.

Quick Summary

  • GHK-Cu is a copper-binding tripeptide studied mainly as a topical skin and wound-research ingredient, not as a conventional oral supplement (Review).
  • The strongest human evidence for GHK-Cu is skin-focused, including a diabetic skin-ulcer trial and topical dermatology studies (Research) (Research).
  • A diabetic skin-ulcer study reported improved wound healing, but that study did not evaluate blood glucose control or diabetes treatment (Research).
  • A post-CO₂-laser skin study reported no clear advantage for topical copper tripeptide complex over comparator groups for redness, swelling, or wound-healing endpoints (Research).
  • Human-skin delivery studies suggest that formulation and barrier status matter, especially when microneedle pretreatment is compared with intact skin (Research).
  • Human Tmax, half-life, and systemic pharmacokinetic profiles are not well established for topical GHK-Cu (Research).
  • Non-human and human-cell studies support mechanistic interest in tissue remodeling, but they do not prove clinical benefit in people (Research) (Review).

Human Research Findings by Condition

Beauty and Skin Health

Human evidence for Beauty and Skin Health is the most relevant clinical area for GHK-Cu because the ingredient has been studied mainly in topical skin, post-procedure skin, and skin-delivery contexts. Findings are mixed: some topical skin studies and reviews report favorable appearance or repair-related findings, while a post-laser clinical study did not show clear benefit over comparator groups (Research) (Review).

Key human study

Dose studied: Topical copper tripeptide complex; concentration not clearly stated in the available study summary.
Population: People with CO₂ laser-resurfaced skin.
Duration: Post-procedure clinical observation period.

Researchers evaluated whether topical copper tripeptide complex improved visible recovery after CO₂ laser resurfacing. The study reported no significant reduction or resolution of post-treatment redness, swelling, or wound-healing endpoints compared with comparator groups (Research).

Result: Human clinical study reported no clear effect
Evidence strength: Limited
Study source: (Research)

Additional human study

Dose studied: Topical copper-binding peptide cream; concentration not clearly stated in the available study report.
Population: Healthy volunteers in a topical cream comparison study.
Duration: 1 month.

A topical cream study compared vitamin C, a copper-binding peptide, melatonin, and tretinoin preparations and measured skin-related endpoints including dermal procollagen synthesis. The copper-binding peptide arm was reported to increase dermal procollagen synthesis in a subset of volunteers, but the study is small and does not provide enough accessible formulation detail for a clear concentration comparison (Research).

Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)

Additional human study

Dose studied: Topical GHK-Cu in skin-care formulations; concentrations vary or are not consistently reported in available summaries.
Population: Adults in topical skin-aging and photodamage-oriented studies summarized in dermatology reviews.
Duration: Commonly weeks to months, depending on the study summarized.

Dermatology reviews describe topical peptide studies in skin-aging contexts, including GHK-Cu-related formulations. These sources support the idea that GHK-Cu has been studied for skin appearance, but some primary cosmetic studies are difficult to interpret because full formulation details and independent replication are limited (Review) (Review).

Result: Human clinical studies reported mixed findings
Evidence strength: Limited
Study source: (Review)

Diabetes and Glycemic Control

GHK-Cu has been studied in people with diabetes through diabetic skin-ulcer healing, usually meaning chronic external skin wounds such as diabetic foot ulcers rather than stomach ulcers. The study belongs near this domain only because the population had diabetes; it does not show that GHK-Cu improves blood glucose, insulin sensitivity, or diabetes control (Research).

Key human study

Dose studied: Topical GHK-Cu; concentration not clearly stated in the PubMed summary.
Population: Patients with diabetic skin ulcers.
Duration: Clinical wound-healing study period.

A multicenter, randomized, evaluator-blinded, placebo-controlled study evaluated topical GHK-Cu for diabetic skin ulcers. The study reported enhanced ulcer healing compared with placebo, making it one of the most clinically relevant human studies for GHK-Cu (Research).

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)

Pain and Acute Inflammation

GHK-Cu has limited human evidence in post-procedure skin contexts where redness, swelling, and wound recovery were measured after laser resurfacing. The available human study did not show a clear advantage for topical copper tripeptide complex on those post-procedure endpoints (Research).

Key human study

Dose studied: Topical copper tripeptide complex; concentration not clearly stated in the available study summary.
Population: People after CO₂ laser resurfacing.
Duration: Post-procedure clinical observation period.

Researchers studied whether topical copper tripeptide complex improved visible post-procedure recovery after laser resurfacing. The study reported no significant reduction or resolution of redness, swelling, or wound-healing endpoints compared with comparator groups (Research).

Result: Human clinical study reported no clear effect
Evidence strength: Limited
Study source: (Research)

Aging and Longevity Research

GHK-Cu is often discussed in aging research because reviews describe effects on tissue remodeling, gene expression, and skin-repair biology. Human evidence in this area is mostly skin-aging related, while broader longevity claims remain mainly mechanistic or preclinical (Review) (Review).

Key human study

Dose studied: Topical GHK-Cu or copper peptide skin-care exposure; exact concentrations are not consistently reported in available summaries.
Population: Adults in topical skin-aging or photodamage-oriented studies summarized in reviews.
Duration: Commonly weeks to months, depending on the study.

Review literature describes topical GHK-Cu-related studies in photoaged skin and reports changes in skin appearance measures. These data are relevant to visible skin aging and Beauty and Skin Health, but they do not establish systemic anti-aging or longevity effects in humans (Review).

Result: Human clinical studies reported mixed findings
Evidence strength: Limited
Study source: (Review)

Bone Health

Human clinical evidence for Bone Health is not established for GHK-Cu in the verified evidence set. The available evidence is mechanistic and comes from human osteoblast-related cell models rather than trials in people (Research).

Key human-cell study

Dose studied: GHK-Cu exposure in cell culture.
Population: Human trabecular osteoblastic cells and human marrow stromal cells in laboratory conditions.
Duration: Laboratory cell-culture exposure period.

Researchers examined how GHK-Cu affected osteoblast-related cell behavior in vitro. The study reported effects on cell attachment and osteoblast phenotype markers, but it was not a human clinical study and should not be read as evidence that GHK-Cu improves bone outcomes in people (Research).

Result: Evidence currently comes mainly from animal or experimental research
Evidence strength: Emerging
Study source: (Research)

Immune System

GHK-Cu has been studied in human-cell and preclinical models related to fibroblast activity, growth-factor signaling, oxidative stress, and inflammatory pathways. These findings support biological plausibility, but they do not establish immune-system benefits in human clinical outcomes (Research) (Review).

Key human-cell study

Dose studied: 1 × 10^-9 mol/L GHK-Cu in cultured cells, approximately 0.00034 micrograms in one liter of fluid.
Population: Primary human dermal fibroblast cell lines, including irradiated fibroblasts.
Duration: Laboratory exposure period.

Researchers exposed normal and irradiated human dermal fibroblasts to an ultra-dilute GHK-Cu concentration and measured cell growth and growth-factor production. The study reported faster fibroblast growth and early increases in selected growth factors in treated irradiated fibroblasts, but this was an in vitro model rather than a clinical trial in people (Research).

Result: Evidence currently comes mainly from animal or experimental research
Evidence strength: Emerging
Study source: (Research)

Neurological Health

Human clinical evidence for GHK-Cu in Neurological Health is not established in the verified evidence set. Review literature discusses preclinical and mechanistic aging-related pathways, but those findings do not show neurological benefit in human clinical studies (Review).

Key preclinical context

Dose studied: Preclinical exposure models; no verified human neurological dose.
Population: Animal and laboratory models summarized in review literature.
Duration: Model-dependent.

A review of GHK as an anti-aging peptide discusses preliminary mechanistic and animal-model evidence. This evidence can support research interest, but it should not be presented as human neurological efficacy evidence (Review).

Result: Evidence currently comes mainly from animal or experimental research
Evidence strength: Emerging
Study source: (Review)

Dosage & Study Snapshot (Research Context)

For GHK-Cu, the most useful human-facing exposure information comes from topical concentration, amount applied, skin-delivery context, and wound-use context, not from oral supplement dosing. Published studies and registered trial entries describe topical products, diabetic skin-ulcer exposure, ex vivo human-skin delivery, microneedle-assisted delivery, and a concentration-disclosed topical gel; human oral dosing, systemic Tmax, and systemic half-life are not well characterized (Research) (FDA).

1 × 10^-9 mol/L GHK-Cu, approximately 0.00034 micrograms in one liter of fluid:

This was an ultra-dilute laboratory concentration used around human dermal fibroblast cells, not a cosmetic-serum percentage or a human application amount. In more familiar terms, 1 × 10^-9 mol/L is roughly 0.00034 micrograms of GHK-Cu in one liter of fluid, assuming a molecular weight near 340 g/mol for GHK-Cu (PubChem). Researchers used this exposure to observe fibroblast growth and growth-factor production in normal and irradiated human dermal fibroblast cells. The study helps explain why GHK-Cu is discussed in tissue-repair biology, but it does not establish a consumer topical concentration or a clinical-use dose (Research).

Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: This exposure applies to cell culture, not direct human use.

Topical GHK-Cu cream, concentration not clearly stated:

Some topical skin studies used GHK-Cu or copper-binding peptide creams without providing enough public detail to calculate percent concentration, mg per gram, or mg per application. One topical cream study compared a copper-binding peptide cream with other topical preparations and reported increased dermal procollagen synthesis in a subset of volunteers after 1 month. The study is relevant because procollagen is part of the skin-support matrix, but the incomplete concentration reporting limits practical dose interpretation. The exposure should therefore be described as a topical study context rather than converted into a guessed concentration (Research).

Result: Modest improvement
Evidence strength: Limited
Notes / limitations: No percentage or mg-per-application estimate should be stated when the study does not clearly provide the needed formulation details.

Topical copper tripeptide complex after CO₂ laser resurfacing, concentration not clearly stated:

A human post-procedure study evaluated whether topical copper tripeptide complex improved recovery after CO₂ laser resurfacing. Researchers measured post-treatment endpoints such as redness, swelling, and wound-healing appearance. The study reported no significant reduction or resolution of those endpoints compared with comparator groups. The available summary does not clearly provide enough formulation detail to convert the exposure into mg/g or mg per application (Research).

Result: No clear effect
Evidence strength: Limited
Notes / limitations: Study length and clinical observation period should not be treated as pharmacokinetic onset, Tmax, or half-life.

Topical GHK-Cu for diabetic skin ulcers, concentration not clearly stated:

A multicenter, randomized, evaluator-blinded, placebo-controlled study evaluated topical GHK-Cu in diabetic skin ulcers. The study tested an external skin-wound outcome and reported enhanced ulcer healing compared with placebo. This is one of the more clinically relevant human studies for GHK-Cu because it evaluated a defined wound-healing endpoint in people. The study supports a diabetic skin-wound context, not a diabetes-control claim, and the available summary does not provide a simple concentration-to-mg conversion (Research).

Result: Statistically significant improvement
Evidence strength: Moderate
Notes / limitations: The study population had diabetes, but the endpoint was skin-ulcer healing rather than blood glucose.

0.1% w/w topical GHK-Cu gel, equal to about 1 mg per gram of gel, with about 0.5 mg planned per application:

A registered U.S. clinical-trial entry described a topical gel containing 0.1% w/w GHK-Cu, equal to about 1 mg of GHK-Cu in each gram of gel if the percentage refers directly to GHK-Cu content. The planned amount applied was about 0.5 g once daily for 14 days, which would equal about 0.5 mg of GHK-Cu per application under that same assumption.

For comparison, a serum-style drop is often roughly 0.03–0.05 mL. If a serum also contained 0.1% GHK-Cu, each drop would contain about 0.03–0.05 mg GHK-Cu, so 0.5 mg GHK-Cu would equal roughly 10–17 drops. This comparison is only an approximate translation because gel weight, serum density, nozzle size, viscosity, and spread area can change the amount delivered per use.

The registered study was designed to evaluate topical GHK-Cu gel for acute standardized skin-wound healing, but the entry describes the planned study design rather than completed published efficacy results. It should therefore be used to understand a real topical exposure level, not as proof that this dose improved skin outcomes (Research).

Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: The study entry provides a planned topical exposure amount, but it does not prove efficacy; drop comparisons are practical approximations, not measured pharmacokinetic doses.

Ex vivo human-skin exposure over 48 hours:

A human-skin penetration study evaluated copper delivery from a copper tripeptide through ex vivo human skin, meaning human skin studied outside the living body under controlled laboratory conditions. Researchers measured retention and penetration to understand how the topical copper peptide moved into or through skin tissue. This kind of study helps explain topical delivery, but it does not establish clinical benefit in living participants. It also does not define systemic Tmax, half-life, or whole-body exposure after consumer use (Research).

Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: Ex vivo skin penetration is delivery evidence, not clinical efficacy evidence.

Microneedle-assisted GHK-Cu delivery over 9 hours:

A human-skin delivery study examined whether polymeric microneedle pretreatment increased GHK-Cu penetration through skin. Researchers compared delivery through intact skin with delivery after microneedle pretreatment, which temporarily changes the skin barrier. The study reported measurable GHK-Cu and copper permeation after microneedle pretreatment, while intact skin showed very limited penetration under the same experimental setup. This supports the idea that barrier disruption can materially change topical delivery, but it does not establish a recommended microneedling protocol or a clinical treatment dose (Research).

Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: This is a delivery study rather than a clinical outcomes trial.

Key Takeaways from Human Research

  • GHK-Cu is most defensibly described as a topical skin and wound-research ingredient, not as a broadly proven systemic supplement (Research) (Review).
  • The clearest human clinical signal comes from a diabetic skin-ulcer study that reported improved healing with topical GHK-Cu (Research).
  • Human topical dermatology findings are mixed because a post-laser study reported no clear benefit on redness, swelling, or wound-healing endpoints (Research).
  • Dose interpretation is limited because several topical studies do not clearly report concentration, amount applied, or mg per application (Research).
  • Human-skin delivery studies show that formulation and skin-barrier status can strongly affect GHK-Cu penetration (Research).
  • FDA’s injectable-route safety-risk discussion supports keeping topical GHK-Cu evidence separate from injectable peptide claims (FDA).

Origin & Natural Occurrence

GHK is a naturally occurring human tripeptide reported in plasma, saliva, and urine. Reviews describe GHK-Cu as the copper-complexed form studied for tissue remodeling, skin repair, and related mechanistic pathways (Review).

GHK-Cu is not well established as a meaningful food-derived ingredient. The available literature frames it primarily as an endogenous peptide complex and as a manufactured topical or research ingredient rather than as a defined dietary source from foods (Review).

Commercial GHK-Cu is generally manufactured for cosmetic, laboratory, or investigational use. This matters because externally applied GHK-Cu should not be assumed to behave like naturally occurring GHK in human fluids (Review).

How It Behaves in the Body

In plain language, GHK-Cu is a small peptide that can bind copper, and copper is involved in many normal biological processes related to tissue structure and repair. That does not mean every copper-containing product behaves like GHK-Cu, and it does not mean topical, oral, and injectable exposure should be interpreted as the same evidence category (Review).

Mechanistic studies describe GHK-Cu as acting on skin-relevant processes such as fibroblast behavior, extracellular-matrix remodeling, and growth-factor signaling. Fibroblasts are cells that help maintain the skin’s support structure, while the extracellular matrix is the surrounding network that includes collagen-related proteins and other structural components (Research) (Review).

A human dermal fibroblast study exposed normal and irradiated fibroblast cells to GHK-Cu and measured cell growth and production of selected growth factors. The study reported increased fibroblast growth and early increases in selected growth factors in irradiated fibroblast models, which supports mechanistic interest in tissue-repair biology but does not prove a cosmetic or wound-healing outcome in people (Research).

The better-supported human-facing evidence is topical and skin-related. The less-established evidence involves systemic anti-aging, neurological, injectable, or oral claims, which remain largely outside the available human clinical evidence base (Review) (FDA).

Absorption & Delivery Formats

Oral immediate-release: Human oral clinical and pharmacokinetic evidence for GHK-Cu is not well established in the verified evidence base. Oral dosing claims should not be extrapolated from topical or cell-culture studies (Review).

Oral extended-release: Human extended-release oral GHK-Cu evidence is not well established in the verified evidence base. Extended-release claims would require direct human formulation studies rather than topical or ex vivo skin data (Review).

Sublingual: Human sublingual pharmacokinetic evidence for GHK-Cu is not well established in the verified evidence base. Sublingual absorption should not be inferred from skin-delivery studies (Research).

Transdermal / topical: Topical and skin-delivery evidence is the most relevant delivery category for GHK-Cu. Ex vivo human-skin studies and microneedle-assisted delivery research show that skin penetration depends on barrier status and delivery method (Research) (Research).

Injectable / IV: FDA identifies injectable-route GHK-Cu in compounding safety-risk materials because of limited human safety data and possible immunogenicity concerns. Injectable GHK-Cu should be treated as a separate safety and regulatory context from topical cosmetic use (FDA).

Quick Facts at a Glance

Onset (reported): A reliable human pharmacological onset time for GHK-Cu is not well characterized. Topical studies report outcomes after clinical observation periods, but a study visit schedule is not the same as biological onset (Research).

Time to peak (Tmax): Human Tmax data are not well established for topical GHK-Cu. Tmax means the time when a substance reaches its highest measured level in blood or another sampled compartment, and ex vivo skin penetration studies do not define systemic Tmax in humans (Research).

Half-life (t½): A reliable human half-life for GHK-Cu has not been clearly established in the available human clinical literature. Half-life means the time it takes for a measured amount of a substance to fall by half, and that value should not be inferred from skin study duration or application frequency (Research).

Typical duration: Study durations vary by context and should be reported as study duration rather than treated as duration of action. For GHK-Cu, clinical observation periods do not substitute for half-life, Tmax, or systemic pharmacokinetic data (Research).

Absorption routes studied: Human-relevant absorption evidence is mainly topical and ex vivo skin-delivery evidence. Microneedle pretreatment increased GHK-Cu delivery through human skin models compared with intact-skin conditions in one study (Research).

Formulation differences: Formulation and barrier status matter because intact skin and microneedle-pretreated skin showed different delivery patterns. This means evidence from one gel, cream, serum, or device-assisted method should not be generalized to all GHK-Cu products (Research).

Variability drivers: Variability may come from skin barrier condition, wound status, concentration, vehicle composition, application amount, and delivery method. Human-skin delivery research directly supports barrier status as a major variable (Research).

Tolerance / adaptation: Long-term tolerance or adaptation to repeated GHK-Cu exposure is not well characterized in the available human evidence. Safety statements should therefore stay close to specific topical studies and official regulatory sources (FDA).

Evidence strength snapshot: Evidence is strongest for topical skin and human-skin delivery contexts, limited for clinical skin outcomes, and mostly mechanistic for systemic claims. This supports an overall Limited / Emerging classification (Review).

Other Physiological Contexts Studied (If Applicable)

  • Human-cell tissue repair models: GHK-Cu increased growth and selected growth-factor production in irradiated human dermal fibroblasts, but this remains mechanistic evidence rather than clinical-outcome evidence (Research).
  • Human osteoblast cell models: GHK-Cu affected cell attachment and osteoblast phenotype markers in human trabecular osteoblastic cells, but this does not establish a bone-health effect in people (Research).
  • Preclinical aging models: Review literature describes animal and cell-model findings related to aging biology, but these findings should not be presented as human longevity evidence (Review).
  • Gene-expression research: Reviews describe broad gene-expression effects of GHK and GHK-Cu, but gene-expression changes are mechanistic signals rather than direct clinical endpoints (Review).

Safety, Interactions & Regulation

Topical GHK-Cu safety should be interpreted within the specific product, concentration, vehicle, skin condition, and study setting. Human topical studies provide limited tolerability context, but they do not establish comprehensive long-term safety across all consumer formulations (Research).

Medication-interaction evidence for GHK-Cu is not well characterized in the available human literature. Because GHK-Cu is a copper-binding peptide and its delivery depends on formulation and route, interaction claims should not be made without direct evidence (Review).

Population cautions are most relevant for damaged skin, chronic wounds, post-procedure skin, pregnancy, allergy-prone individuals, and anyone considering non-topical routes. These cautions reflect limited direct human safety evidence rather than a mature safety database (Research) (FDA).

In the U.S., FDA states that cosmetic products and ingredients generally do not need FDA premarket approval, except for color additives, but firms remain responsible for product safety and labeling compliance (FDA). FDA separately lists GHK-Cu for injectable routes of administration among bulk drug substances that may present significant safety risks in compounding, citing possible immunogenicity and limited human safety data (FDA).

In the EU cosmetic ingredient database, Copper Tripeptide-1 is identified as a copper complex of Tripeptide-1 (EFSA). The CosIng listing identifies the ingredient and does not establish clinical efficacy (EFSA).

Evidence Overview

The human evidence for GHK-Cu is strongest in topical skin and diabetic skin-ulcer research, while systemic, oral, injectable, neurological, and broad anti-aging claims remain weakly supported in humans. A diabetic skin-ulcer trial reported improved healing with topical GHK-Cu, but a post-CO₂-laser study reported no clear advantage for redness, swelling, or wound-healing endpoints compared with comparator groups (Research) (Research). Confidence is limited because the clinical literature is small, study settings differ, formulation details are often incomplete, and many supportive findings come from human-cell, animal, or mechanistic studies rather than replicated human trials (Review).

Mechanistic evidence explains why GHK-Cu remains scientifically interesting. Human dermal fibroblast research reported increased fibroblast growth and early growth-factor production in irradiated fibroblast models, and reviews describe effects on extracellular-matrix remodeling and gene-expression pathways (Research) (Review). These findings support biological plausibility, but they do not prove clinical benefit in people.

Delivery evidence is central to interpreting GHK-Cu because the ingredient is most often discussed as a topical copper peptide. Ex vivo human-skin studies show that penetration and retention can be measured, and microneedle pretreatment can change delivery through human skin models (Research) (Research). This means evidence from one formulation or delivery method should not be generalized across all GHK-Cu products.

The weakest evidence areas are oral use, injectable use, systemic longevity claims, neurological claims, and generalized recovery claims. Review literature discusses GHK-Cu in relation to aging and tissue repair, but much of that evidence is preclinical or mechanistic (Review). FDA’s injectable-route safety-risk discussion also supports separating topical cosmetic and wound research from injectable peptide claims (FDA).

Future confidence would require larger randomized human trials, transparent concentration reporting, standardized topical vehicles, direct human pharmacokinetic studies, longer safety follow-up, and independent replication. Until then, GHK-Cu is best described as a topical and mechanistically active copper peptide with limited but relevant human skin evidence (Review).

Evidence Confidence Classification

Limited / Emerging is the overall human evidence classification for GHK-Cu because human research is small, mostly topical, and mixed across skin-related outcomes, while many broader claims rely on mechanistic or preclinical evidence (Research) (Research) (Review).

The evidence is strongest for topical skin and diabetic skin-ulcer research. The evidence is weaker for oral, injectable, neurological, systemic anti-aging, and broad recovery claims because those areas lack mature human clinical support in the verified evidence base (Review) (FDA).

Similar Ingredients & Comparators

Similar supplement-style or cosmetic-style ingredients:

  • Palmitoyl tripeptide-1
  • Palmitoyl tetrapeptide-7
  • Matrixyl 3000 peptide blend
  • Acetyl hexapeptide-8
  • Carnosine
  • Hyaluronic acid
  • Niacinamide
  • Vitamin C derivatives
  • Retinoids
  • Copper-containing topical materials

Medical / pharma comparator categories:

  • Prescription topical retinoids
  • Wound-care dressings
  • Growth-factor wound therapies
  • Post-procedure dermatology products
  • Barrier-repair topical agents
  • Antimicrobial wound-care materials

Combination Context

GHK-Cu + topical cosmetic vehicles:
GHK-Cu is commonly studied in topical vehicles because skin delivery depends on the formulation and the skin barrier. Human-skin penetration research supports formulation-dependent interpretation, but it does not prove that all GHK-Cu creams or serums deliver the ingredient similarly (Research).

GHK-Cu + microneedle-assisted delivery:
Microneedle-assisted delivery has been studied because intact skin can limit peptide penetration. A human-skin delivery study reported increased GHK-Cu and copper permeation after microneedle pretreatment, but this was a delivery experiment rather than a clinical-use recommendation (Research).

GHK-Cu + post-procedure dermatology care:
Topical copper tripeptide complex has been studied after CO₂ laser resurfacing to evaluate redness, swelling, and wound recovery. The study reported no clear advantage over comparator groups, so this combination context remains limited and mixed (Research).

GHK-Cu + diabetic skin-ulcer care context:
Topical GHK-Cu has been studied in diabetic skin ulcers as part of wound-healing research. The trial reported enhanced skin-ulcer healing, but it should not be generalized to blood glucose control or all chronic wounds without additional evidence (Research).

FAQ

What is this ingredient?

GHK-Cu is a copper-binding tripeptide complex also known as Copper Tripeptide-1 (Review). GHK is described as a naturally occurring human peptide found in plasma, saliva, and urine (Review). In cosmetic ingredient databases, Copper Tripeptide-1 is identified as a copper complex of Tripeptide-1 (EFSA).

What does human research study it for?

Human research studies GHK-Cu mainly for topical skin outcomes and diabetic skin-ulcer healing. The verified evidence includes a diabetic skin-ulcer trial, a post-laser skin study, topical cosmetic research, and human-skin delivery studies (Research) (Research) (Research). Broader systemic claims are mostly supported by mechanistic or preclinical research rather than mature human trials (Review).

What are the best-supported uses?

The best-supported research area is topical skin and wound-related research. A diabetic skin-ulcer trial reported improved healing with topical GHK-Cu, while topical dermatology studies provide smaller and more mixed evidence for skin appearance and post-procedure recovery (Research) (Research). This evidence does not establish GHK-Cu as a treatment for diabetes, systemic aging, or neurological conditions (Review).

Where is evidence mixed or limited?

Evidence is mixed in topical dermatology because one diabetic skin-ulcer study reported improved healing, while a post-laser study found no clear benefit on redness, swelling, or wound-healing endpoints (Research) (Research). Evidence is limited for oral use, injectable use, neurological claims, and broad anti-aging claims because those areas rely mainly on preclinical or mechanistic evidence (Review). Dose interpretation is also limited because several topical studies do not clearly disclose concentration or amount applied (Research).

How quickly does it act?

A reliable human pharmacological onset time for GHK-Cu is not well characterized. Topical studies measure outcomes after observation periods, but those observation periods are not the same as biological onset (Research). Ex vivo human-skin studies measure delivery over laboratory timeframes, but they do not establish clinical onset in humans (Research).

What affects absorption and variability?

Absorption and variability are likely affected by skin barrier status, formulation, concentration, application amount, wound status, and delivery method. A microneedle study reported greater GHK-Cu delivery through human skin models after microneedle pretreatment compared with intact skin (Research). Ex vivo human-skin penetration research supports the view that topical delivery is measurable but highly context-dependent (Research).

Is tolerance reported?

Long-term tolerance or adaptation to GHK-Cu is not well characterized in the available human evidence. Individual topical studies provide limited safety context, but they do not establish a comprehensive long-term safety profile across all formulations and routes (Research). Injectable-route safety is a separate concern because FDA has flagged limited human safety data and possible immunogenicity risks for compounded injectable GHK-Cu (FDA).

Why do studies disagree?

Studies may disagree because they use different populations, outcomes, vehicles, concentrations, and skin conditions. A diabetic skin-ulcer trial and a post-laser resurfacing trial tested different clinical situations, so their results should not be expected to match directly (Research) (Research). Delivery studies also show that skin-barrier status can change GHK-Cu penetration, which makes formulation and application context important (Research).

How many drops of a GHK-Cu serum would match the 0.5 mg topical exposure described in the registered study?

A registered U.S. clinical-trial entry described a planned topical exposure of about 0.5 mg GHK-Cu per application from a 0.1% w/w gel, assuming the stated percentage refers directly to GHK-Cu content (Research). In a 0.1% GHK-Cu serum, a typical 0.03–0.05 mL drop would contain about 0.03–0.05 mg GHK-Cu, so 0.5 mg would equal roughly 10–17 drops. In a 1% GHK-Cu serum, each drop would contain about 0.3–0.5 mg GHK-Cu, so 0.5 mg would equal roughly 1–2 drops. These are concentration translations, not dosing advice, because actual delivery depends on dropper size, viscosity, spread area, skin barrier status, and formulation.

What ingredients is it commonly combined with and why?

GHK-Cu is commonly discussed with topical vehicles, peptide blends, barrier-support ingredients, and device-assisted delivery methods because topical delivery is central to its evidence base. Microneedle-assisted delivery has been studied to examine whether barrier disruption changes skin penetration (Research). Cosmetic peptide reviews discuss GHK-Cu within the broader topical peptide category, but they do not prove that all combinations produce additive clinical effects (Review).

What foods naturally contain this ingredient?

GHK-Cu is not well established as a meaningful food-derived ingredient. Reviews describe GHK as naturally occurring in human biological fluids rather than as a defined nutrient from specific foods (Review). Food-source claims for intact GHK-Cu should be avoided unless direct analytical evidence is verified (Review).

How is it regulated?

In the U.S., FDA states that cosmetic products and ingredients generally do not require FDA premarket approval except color additives, but companies remain responsible for product safety and labeling compliance (FDA). FDA separately lists injectable-route GHK-Cu in compounding safety-risk materials because of limited human safety data and possible immunogenicity concerns (FDA). In the EU CosIng database, Copper Tripeptide-1 is identified as a copper complex of Tripeptide-1 (EFSA).

Resources

More from the Supplement Ingredients & Medical Ingredients Encyclopedia​

No Result
View All Result

© 2026 SHIZAM Limited. All rights reserved.